comparemela.com

Latest Breaking News On - Gene correction - Page 4 : comparemela.com

Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

/PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with.

United statesLos angelesAmerican society of genePrnewswire poseida therapeutics incTechnology reactivates fetal hemoglobinPoseida therapeutics incTechnology enables precise gene editingLos angeles convention centerAmerican societyCell therapyAnnual meetingPreclinical proof of conceptNovel hybrid gene therapy approachGastrointestinal diseasesEnables precise gene editingSite specific transgene insertion

Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting

/PRNewswire/ Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral.

United statesAaron jaffeLos angelesSahar abubuckerVic myerHead of researchChroma medicine incAmerican society of gene cell therapyAmerican societyCell therapyAnnual meetingTargeted epigenetic editorNear complete in vivo silencingSenior vice presidentGene targetingGene correction

Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results

10.05.2022 - Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in .

New zealandUnited kingdomUnited statesJen robinsonGina nugentAndrew bellingerSekar kathiresanEditing to treatGlobal clinical developmentEditing of in vivo base medicinesVerve therapeutics incResearch development rd expensesExchange commissionAmerican society of geneCash equivalentsMarketable securities

EdiGene to Present getools, a Data Analysis Software Toolkit for Advanced Analytics of DNA and RNA E

BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) BEIJING and CAMBRIDGE, MASS. – (May 2, 2022) – EdiGene, Inc., a global, clinical-stage biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, will present getools (gene ed.

United statesUnited kingdomDong weiXiaomeng zhangAmerican society of gene cell therapyEdigene incAmerican societyCell therapyAnnual meetingEnables ultra fastAccurate quantificationGene editing outcomesBoth bulkSingle cell dataGenome editing experimentsWednesday may

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Soci

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS® gene editing therapiesDURHAM, N.C. (BUSINESS WIRE) $DTIL #ARCUS Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic.

United statesMei burrisPrecision biosciences incUniversity of pennsylvania gene therapy programDtil biosciences incAmerican society of gene cell therapyWaltere washington convention centerPrecision biosciencesAmerican societyCell therapyConvention centerEliminate hepatitisb virus in vivoGene editingComplex diseasesSustained transductionInfant macaque

vimarsana © 2020. All Rights Reserved.